A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B

Study Summary

The purpose of this study is to evaluate the safety of single ascending IV doses of a Factor IX (FIX) Gene Therapy in up to 16 Adults with Hemophilia B.

Interventions

Study Locations

Facility	City	State	Country
Orthopaedic Hemophilia Treatment Center	Los Angeles	California	United States
Children's Hospital Los Angeles	Los Angeles	California	United States
University of California Davis Medical Center	Sacramento	California	United States
University of California at San Diego Medical Center	San Diego	California	United States
U of Colorado School of Medicine, Hemophilia & Thrombosis Treatment Center	Aurora	Colorado	United States
Emory University	Atlanta	Georgia	United States
Rush University Medical Center	Chicago	Illinois	United States
Children's Hospital of Boston	Boston	Massachusetts	United States
University of Minnesota, Masonic Clinical Research Unit, Clinical and Translational Science Institute	Minneapolis	Minnesota	United States
Mount Sinai Medical Center	New York	New York	United States
The Hemophilia Center, Oregon Health and Science University	Portland	Oregon	United States
Medical University of South Carolina	Charleston	South Carolina	United States
Gulf States Hemophilia and Thrombosis Center	Houston	Texas	United States
Bloodworks Northwest	Seattle	Washington	United States
BloodCenter of Wisconsin	Milwaukee	Wisconsin	United States

Official Trial Information

View on ClinicalTrials.gov